Harrow Health, Inc. (HROW)
USD 23.86
(2.18%)
USD 23.86
(2.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.72 Million USD | 573.27% |
| 2022 | -3.2 Million USD | -9.14% |
| 2021 | -10.14 Million USD | 90.1% |
| 2020 | 3.49 Million USD | -48.56% |
| 2019 | 1.43 Million USD | 172.46% |
| 2018 | -2.73 Million USD | 79.97% |
| 2017 | -10.39 Million USD | -26.24% |
| 2016 | -14.05 Million USD | 17.03% |
| 2015 | -14.21 Million USD | -41.71% |
| 2014 | -10.06 Million USD | -31.31% |
| 2013 | -7.63 Million USD | -83.57% |
| 2012 | -5.35 Million USD | -343.13% |
| 2011 | -878.59 Thousand USD | 62.46% |
| 2010 | -2.47 Million USD | 45.19% |
| 2009 | -4.55 Million USD | -10.73% |
| 2008 | -4.12 Million USD | -49.95% |
| 2007 | -2.74 Million USD | -5847.39% |
| 2006 | -46.2 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.73 Million USD | 157.4% |
| 2024 Q1 | -3.74 Million USD | -196.54% |
| 2023 Q2 | 2.35 Million USD | 94.38% |
| 2023 Q1 | 1.21 Million USD | 168.05% |
| 2023 Q3 | 1.74 Million USD | -25.85% |
| 2023 FY | - USD | 573.27% |
| 2023 Q4 | -1.61 Million USD | -192.43% |
| 2022 Q1 | 162 Thousand USD | 112.89% |
| 2022 FY | - USD | -9.14% |
| 2022 Q4 | -1.77 Million USD | 36.07% |
| 2022 Q3 | -2.78 Million USD | -55720.0% |
| 2022 Q2 | 5000.00 USD | -96.91% |
| 2021 Q3 | -3.85 Million USD | -202.12% |
| 2021 FY | - USD | 90.1% |
| 2021 Q1 | -585 Thousand USD | -122.28% |
| 2021 Q2 | 3.77 Million USD | 745.81% |
| 2021 Q4 | -1.25 Million USD | 67.42% |
| 2020 Q1 | -851 Thousand USD | 40.28% |
| 2020 Q3 | 1.25 Million USD | 136.6% |
| 2020 FY | - USD | -48.56% |
| 2020 Q2 | -3.43 Million USD | -303.88% |
| 2020 Q4 | 2.62 Million USD | 108.74% |
| 2019 FY | - USD | 172.46% |
| 2019 Q1 | 26 Thousand USD | -99.35% |
| 2019 Q2 | -1.61 Million USD | -6296.15% |
| 2019 Q3 | 9.78 Million USD | 707.64% |
| 2019 Q4 | -1.42 Million USD | -114.56% |
| 2018 Q2 | -5.48 Million USD | -314.98% |
| 2018 Q3 | -167 Thousand USD | 96.96% |
| 2018 Q4 | 3.99 Million USD | 2491.62% |
| 2018 Q1 | -1.32 Million USD | 20.89% |
| 2018 FY | - USD | 79.97% |
| 2017 Q4 | -1.67 Million USD | -22.42% |
| 2017 Q3 | -1.36 Million USD | 83.08% |
| 2017 Q2 | -8.06 Million USD | -113.38% |
| 2017 FY | - USD | -26.24% |
| 2017 Q1 | -3.78 Million USD | -244.67% |
| 2016 Q4 | -1.09 Million USD | 69.35% |
| 2016 Q2 | -3.64 Million USD | -5.22% |
| 2016 Q3 | -3.57 Million USD | 1.89% |
| 2016 FY | - USD | 17.03% |
| 2016 Q1 | -3.46 Million USD | 23.55% |
| 2015 Q3 | -3.35 Million USD | -0.84% |
| 2015 Q4 | -4.53 Million USD | -35.09% |
| 2015 FY | - USD | -41.71% |
| 2015 Q1 | -2.99 Million USD | -10.39% |
| 2015 Q2 | -3.32 Million USD | -11.3% |
| 2014 Q2 | -2.56 Million USD | -10.6% |
| 2014 FY | - USD | -31.31% |
| 2014 Q4 | -2.7 Million USD | -11.59% |
| 2014 Q3 | -2.42 Million USD | 5.48% |
| 2014 Q1 | -2.32 Million USD | -23.55% |
| 2013 Q4 | -1.87 Million USD | 9.45% |
| 2013 FY | - USD | -83.57% |
| 2013 Q1 | -1.46 Million USD | -0.85% |
| 2013 Q2 | -2.21 Million USD | -51.37% |
| 2013 Q3 | -2.07 Million USD | 6.35% |
| 2012 Q3 | -1.24 Million USD | -11.97% |
| 2012 Q2 | -1.11 Million USD | -216.3% |
| 2012 FY | - USD | -343.13% |
| 2012 Q1 | -351.51 Thousand USD | -12.25% |
| 2012 Q4 | -1.45 Million USD | -16.64% |
| 2011 Q2 | -145.69 Thousand USD | 64.77% |
| 2011 Q1 | -413.55 Thousand USD | -8.77% |
| 2011 Q3 | -66.49 Thousand USD | 54.36% |
| 2011 Q4 | -313.14 Thousand USD | -370.92% |
| 2011 FY | - USD | 62.46% |
| 2010 FY | - USD | 45.19% |
| 2010 Q3 | -727.5 Thousand USD | -39.16% |
| 2010 Q2 | -522.79 Thousand USD | 39.94% |
| 2010 Q1 | -870.48 Thousand USD | -12.14% |
| 2010 Q4 | -380.2 Thousand USD | 47.74% |
| 2009 FY | - USD | -10.73% |
| 2009 Q1 | -1.62 Million USD | -68.79% |
| 2009 Q4 | -776.25 Thousand USD | 16.44% |
| 2009 Q3 | -928.97 Thousand USD | 24.48% |
| 2009 Q2 | -1.23 Million USD | 24.43% |
| 2008 Q4 | -964.35 Thousand USD | -215.54% |
| 2008 Q1 | -1.04 Million USD | 32.94% |
| 2008 FY | - USD | -49.95% |
| 2008 Q3 | 834.67 Thousand USD | 165.19% |
| 2008 Q2 | -1.28 Million USD | -22.89% |
| 2007 FY | - USD | -5847.39% |
| 2007 Q2 | -1109.00 USD | 41.54% |
| 2007 Q3 | 969.14 Thousand USD | 87489.0% |
| 2007 Q4 | -1.55 Million USD | -260.33% |
| 2007 Q1 | -1897.00 USD | 34.65% |
| 2006 Q4 | -2903.00 USD | 62.46% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | -7733.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 96.847% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 513.567% |
| Embecta Corp. | 245.4 Million USD | 96.038% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 94.031% |
| PainReform Ltd. | -9.56 Million USD | 201.609% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 354.235% |
| SCYNEXIS, Inc. | 73.47 Million USD | 86.768% |
| Journey Medical Corporation | 1.92 Million USD | -406.143% |
| Safety Shot Inc | -12.18 Million USD | 179.794% |
| Alpha Teknova, Inc. | -25.53 Million USD | 138.071% |
| Bright Green Corporation | - USD | -Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 90.653% |
| Alvotech | -484.86 Million USD | 102.005% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 91.106% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -722.589% |
| Cosmos Health Inc. | -17.06 Million USD | 156.987% |
| Dynavax Technologies Corporation | 9.66 Million USD | -0.59% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 106.477% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 106.121% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 354.235% |
| Theratechnologies Inc. | -10.31 Million USD | 194.281% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 314.873% |
| Biofrontera Inc. | -18.45 Million USD | 152.691% |
| DURECT Corporation | -24.68 Million USD | 139.39% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 90.105% |
| Cronos Group Inc. | -72.14 Million USD | 113.476% |
| OptiNose, Inc. | -15.55 Million USD | 162.515% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 101.051% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 126.947% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 62.983% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 73.015% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 347.887% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 1467.799% |
| Radius Health, Inc. | 38.31 Million USD | 74.62% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 402.42% |
| ProPhase Labs, Inc. | -14.82 Million USD | 165.576% |
| Phibro Animal Health Corporation | 84.6 Million USD | 88.508% |
| Procaps Group S.A. | 104.02 Million USD | 90.653% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 215.736% |
| Viatris Inc. | 3.51 Billion USD | 99.724% |
| Rockwell Medical, Inc. | -4.69 Million USD | 307.137% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 1060.771% |
| SIGA Technologies, Inc. | 84.15 Million USD | 88.447% |
| Tilray Brands, Inc. | -72.84 Million USD | 113.348% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -1097.414% |
| Shineco, Inc. | -26.55 Million USD | 136.616% |
| PetIQ, Inc. | 81.48 Million USD | 88.068% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 368.767% |
| Incannex Healthcare Limited | -18.5 Million USD | 152.545% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 97.663% |
| Alimera Sciences, Inc. | 7.27 Million USD | -33.631% |
| Silver Spike Investment Corp. | 7.34 Million USD | -32.464% |
| Assertio Holdings, Inc. | -222.44 Million USD | 104.371% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 343.645% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 330.848% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 157.861% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 148.54% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 106.52% |
| Hempacco Co., Inc. | -12.77 Million USD | 176.12% |
| Talphera, Inc. | -9.84 Million USD | 198.791% |
| Alvotech | -484.86 Million USD | 102.005% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 87.455% |
| Lantheus Holdings, Inc. | 491 Million USD | 98.02% |
| Currenc Group, Inc. | -1.9 Million USD | 611.582% |
| Kamada Ltd. | 21.53 Million USD | 54.848% |
| Indivior PLC | 66 Million USD | 85.268% |
| Evoke Pharma, Inc. | -7.29 Million USD | 233.333% |
| Flora Growth Corp. | -45.87 Million USD | 121.197% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 148.54% |
| Evolus, Inc. | -41.81 Million USD | 123.255% |
| HUTCHMED (China) Limited | 25.52 Million USD | 61.912% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 95.973% |
| Akanda Corp. | -27.73 Million USD | 135.056% |